These findings suggest that the pharmacological antitumor activity of MC4R inhibition is strongly associated with the suppression of ERK1/2 phosphorylation, as we have already also observed in glioblastoma cells previously [16]. The gene discussed is MAPK3; the disease is glioblastoma.